Glucose-Responsive Microgels for Closed-Loop Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin delivery systems for diabetes management are inadequate as they exhibit long glucose response times and fail to precisely match physiological insulin needs, leading to inadequate blood glucose control and increased risk of hypoglycemic complications.
Innovation Solution
Development of injectable insulin-loaded microgels that are responsive to tissue glucose levels, comprising a glucose oxidizing agent, a pH-responsive polymeric scaffold, and exogenous insulin, which swell and release insulin in response to increased glucose, thereby controlling insulin delivery based on physiological needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional insulin delivery systems are used, then insulin is delivered continuously or at fixed intervals, but the response time to glucose changes is too long and cannot match physiological needs
Solution Approach 1:
The patent utilizes pH-responsive polymers that change their physical state (swelling/deswelling) in response to glucose-induced pH changes. Glucose oxidase converts glucose to gluconic acid, lowering pH and triggering polymer swelling that releases insulin. This parameter-based response mechanism enables rapid insulin delivery within minutes of glucose elevation, matching physiological response times while maintaining reliable blood glucose control.
Solution Approach 2:
The patent replaces mechanical injection systems or electronic pumps with a chemically-driven autonomous system. The glucose oxidase enzyme-catalyzed reaction generates H+ ions that trigger pH-responsive polymer swelling, creating a self-regulating chemical-mechanical system that responds automatically to glucose levels without external control, achieving both rapid response and reliable control.
2Loss of time
If glucose oxidase-based pH-responsive hydrogel systems are used, then insulin release is triggered by glucose, but the glucose response time is very long
Solution Approach 1:
The patent employs thin film microgels with high surface-area-to-volume ratios that enable rapid glucose diffusion and quick pH response. The flexible polymer network structure allows rapid swelling and deswelling transitions, reducing glucose response time from hours to minutes while maintaining high insulin release rates through efficient mass transport across the thin gel matrix.
Solution Approach 2:
The patent segments the insulin delivery system into discrete microgel particles containing glucose oxidase and pH-responsive polymer. This segmentation increases the surface area for glucose interaction and enables rapid, distributed insulin release throughout the injection site, improving both response speed and release rate compared to bulk hydrogel systems.
3Reliability
If open-loop insulin delivery is used, then insulin is administered at fixed schedules, but blood glucose cannot be maintained at normal levels during fluctuations
Solution Approach 1:
The patent creates a self-service insulin delivery system where glucose oxidase automatically detects glucose levels and triggers pH changes that release insulin without external intervention. The system self-regulates by converting excess glucose to acid, which then triggers polymer swelling and insulin release, maintaining normoglycemia reliably while keeping the system structure simple and injection-based.
Solution Approach 2:
The patent implements a chemical feedback loop where glucose oxidation generates H+ ions that serve as the feedback signal triggering insulin release. When glucose levels rise, more acid is produced, increasing polymer swelling and insulin release rate, thereby automatically correcting hyperglycemia and maintaining reliable blood glucose control through inherent feedback control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microgel system provides a rapid and controlled release of insulin in response to glucose fluctuations, effectively maintaining normoglycemic blood glucose levels and reducing the risk of hypoglycemia, with a reversible mechanism that ceases insulin release under normoglycemic conditions.
Implementation Method 1
The conversion of glucose to gluconic acid, catalyzed by glucose oxidase, lowers the pH affecting the swelling of pH sensitive hydrogels
Implementation Method 2
The conversion of glucose to gluconic acid, catalyzed by glucose oxidase
Implementation Method 3
This swelling allows a release of insulin in response to an increase in glucose concentrations in the immediate environment
Implementation Method 4
a pH-responsive polymeric scaffold, such as a physically cross-linked pH-responsive polymeric matrix
Data Source
AI summary
Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel.